Matt Sagan: Moving from HER2+ to HER2-low to HER2- ultralow
Matt Sagan, of FiBioMed, shared a post by Paolo Tarantino on X, adding:
“It took us 24 years to move from HER2+ to HER2 low And it took is 2 years from HER2 low to HER2 ultralow.
Stay tuned! Interesting what 2025 will bring in that space.”
Quoting Paolo Tarantino’s post:
- “1998: the FDA approves trastuzumab. HER2+ becomes clinically relevant.
- 2022: T-DXd improves outcomes in HER2-low MBC. HER2-low becomes clinically relevant.
- 2024: T-DXd improves outcomes in HER2-low and ultra low. HER2-ultralow becomes clinically relevant.
Stay tuned.”
Source: Matt Sagan/X and Paolo Tarantino/X
Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.